- Home
- BMBL vs CTMX Comparison
BMBL vs CTMX Comparison
Compare BMBL & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BMBL | CTMX |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 545.0M | 596.2M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | BMBL | CTMX |
|---|---|---|
| Price | $3.78 | $3.89 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 6 |
| Target Price | $5.17 | ★ $6.50 |
| AVG Volume (30 Days) | ★ 2.9M | 2.4M |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 50.22 |
| EPS | N/A | ★ 0.24 |
| Revenue | ★ $1,003,141,000.00 | $113,631,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.28 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.18 | $0.40 |
| 52 Week High | $8.82 | $4.62 |
Technical Indicators
Market Signals| Indicator | BMBL | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 41.54 | 51.40 |
| Support Level | $3.57 | $3.66 |
| Resistance Level | $3.78 | $4.20 |
| Average True Range (ATR) | 0.19 | 0.24 |
| MACD | 0.10 | -0.04 |
| Stochastic Oscillator | 97.61 | 43.84 |
Price Performance
Historical ComparisonAbout BMBL Bumble Inc.
Bumble Inc is engaged in offering online dating services. The platform enables people to connect and build healthy and equitable relationships on their own terms. The company operates two apps, Bumble and Badoo, where users come every month to discover new people and connect. The company Operates in USA and also Internationally such as United Kingdom, Czech Republic, and others with maximum of revenue from Other Countries.
About CTMX CytomX Therapeutics Inc.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.